THURSDAY, AUGUST 17, 2017

VBI provides update on hepatitis C vaccine research at conference

VBI Vaccines updates industry representatives and leaders on its hepatits C vaccine research this week at the World Vaccine Congress Asia in Singapore.. | Courtesy of hepatitiscnewdrugresearch.com

VBI Vaccines recently presented the latest data about its eVLP platform being used in creating a new hepatitis C vaccine candidate at the World Vaccine Congress Asia, held Wednesday and Thursday at the Suntec Singapore Convention & Exhibition Centre in Singapore.

The new hepatitis C vaccine candidate uses the company’s eVLP vaccine platform to create enveloped (“e”) virus-like particle (“VLP”) vaccines. These eVLPs are now a novel class of synthetic vaccines that can be engineered to be very similar to a typical virus structure. This structure, which is commonly found in nature, enables eVLPs to provoke a stronger response from the immune system than the regular recombinant target protein.

The presentation, titled "Enveloped Virus-Like Particles: Third-Generation VLPs for the Development of Broadly Neutralizing Hepatitis C Vaccine, was presented by Jeff Baxter, president and CEO of VBI Vaccines.

"VBI has previously demonstrated strong cross-reactive neutralizing antibody responses against multiple genotypes of (hepatitis C virus) in monkeys," Baxter said. "Based on this data, we believe our HCV vaccine candidate has the potential to be a promising and safe component of HCV treatment regimens, especially in areas where the transmission of Hepatitis C has not yet been adequately addressed by the existing field of approved and available drugs."

Organizations in this story

VBI Vaccines Inc 222 Third St Cambridge, MA - 02142

Get notified the next time we write about VBI Vaccines Inc!